|
Market Cap (5-Jul) $6,838,995 (1,207th) |
Close (30-Jun) $0.200 |
Volume (30-Jun) 1,808,064 |
Shortsold (12-Jun) 8,499 (0.01%) (521st) |
|
52w High $0.100 |
52w Low $0.059 |
P/E - |
EPS 0 |
IXC released this announcement to the ASX on 4 November 2021, 9:12. The announcement is marked as price sensitive, and is 5 page(s) in length and 275.06kb in size.
You can view all announcements from IXC and see how they appear on a price chart on the announcements page.
At the date of this announcement, IXC was 0.461% short sold according to ASIC data. It was ranked the 289th most shorted stock on the ASX. It remains ranked 521st as of the latest reported data (12 June 2025).
| Other Recent Announcements from IXC | |
|---|---|
| Phase III Clinical Trial Update and New IIH Market Analysis | 28 June 2023, 8:40 |
| Invex Granted European Orphan Drug Designation for TBI | 23 June 2023, 8:18 |
| Invex Receives Regulatory Approval for IIH EVOLVE in France | 21 April 2023, 8:17 |
| Global Phase 3 Trial of Presendin to Launch in Q4 2021 | 4 November 2021, 9:12 |
| Notice of Annual General Meeting/Proxy Form | 25 October 2021, 9:38 |
| Quarterly Activities/Appendix 4C Cash Flow Report | 20 October 2021, 8:35 |
| Presentation at EANS 2021 Congress | 8 October 2021, 9:04 |
You must be logged in to post a reply.
Invex Therapeutics Ltd 